Introduction {#S1}
============

Recurrent deletions and duplications at the subchromosomal region 1q21.1 (GRCh37/hg19, chr1:144.0--149.5 Mb) have been reported in patients with diverse clinical features ([@B9]; [@B34]; [@B13]; [@B20]). The mechanism of chromosomal deletion and duplication is most likely due to segmental duplications (a.k.a., low copy repeats) in the region ([@B9]). These low copy repeats cluster together and form four segmental duplication blocks with a size range of 270 kb--2.2 Mb, making this subchromosomal region a hotspot for non-allelic homologous recombination (NAHR) ([@B34]; [@B13]; [@B20]). Not surprisingly, chromosomal breakpoints (BPs) in patients with 1q21.1deletions and duplications have been exclusively mapped to the four segmental duplication blocks, designated as BP1--BP4 according to the orientation from centromere to telomere ([@B9]; [@B36]).

As hundreds of individuals possessing the 1q21.1 deletions or the reciprocal duplications manifest phenotypic abnormalities, documentation and categorization of three syndromes have been included in the Online Mendelian Inheritance in Man (OMIM). Those rare disorders include chromosome 1q21.1 deletion syndrome (MIM 612474), chromosome 1q21.1 duplication syndrome (MIM 612475), and TAR syndrome (MIM 274000). Chromosome 1q21.1 deletion and duplication syndromes share certain clinical phenotypes such as developmental delays, craniofacial abnormalities, and cardiac anomalies. Other relative common phenotypes include intellectual disabilities (IDs), attention deficit hyperactive disorders, autism spectrum disorder, and schizophrenia ([@B9]; [@B34]; [@B24]; [@B44]; [@B45]; [@B7]; [@B10]). Contrastingly, patients with 1q21.1 deletion syndrome are more likely to display features of microcephaly and/or schizophrenia, whereas carriers of 1q21.1 duplications are inclined to present symptoms of macrocephaly and/or autism ([@B34]; [@B29]; [@B14]; [@B20]; [@B18]). Based on the molecular sizes of CNVs, 1q21.1 deletions and duplications have been grouped into two classes ([@B9]). The class I deletions and reciprocal duplications typically occur at the 1q21.1 distal region between BP3 and BP4 with a size range of 800 kb--2 Mb, and the class II deletions and reciprocal duplications commonly reside between BP1/BP2 and BP4 with relatively bigger sizes of ∼3 Mb or larger ([@B9]; [@B13]).

Thrombocytopenia-absent radius syndrome was initially reported in the 1950s, with the diagnostic criteria for this syndrome defined by Hall et al. in 1969 ([@B22]; [@B41]; [@B23]). The characteristic features of TAR syndrome are bilateral absence of radial bones in the forearms and thrombocytopenia (\<50 platelets/nl) ([@B1]). Less common symptoms include hand and foot abnormalities, congenital heart defects, renal anomalies, and cow milk intolerance ([@B21]; [@B36]; [@B1]). Nevertheless, it was only until recently that the genetic basis and the inheritance pattern of TAR syndrome were ascertained ([@B28]). Most patients diagnosed with TAR syndrome have compound heterozygous mutations, including a deletion at the proximal 1q21.1 region (a.k.a., TAR deletion), with a minimal size of 200 kb that encompasses the RBM8A gene and a point mutation in the non-coding region of RBM8A ([@B1]; [@B43]). Remarkably, the reciprocal duplication of the TAR deletion region, also being called proximal 1q21.1 duplication, is significantly enriched in patients with variable clinical features when compared to control groups in the two large cohort studies ([@B13]; [@B36]). In one report, [@B36] proposed that the proximal 1q21.1 duplications were causative to the patients' phenotypical features. However, more supportive evidence is needed to refine their roles in the symptoms manifested in the patients.

To better understand the disorders associated with deletions and duplications at the 1q21.1 locus, we investigated more than 5,200 clinical tests conducted in the last 10 years at our laboratory that has been accredited by the College of American Pathologist (CAP) since 2000. Our investigation resulted in 36 cases with one causative or likely causative variant at the 1q21.1 locus. Molecular characterizations and clinical manifestations are described.

Materials and Methods {#S2}
=====================

Patients and Sample Collections {#S2.SS1}
-------------------------------

Most of the patients were from the state of Oklahoma, which has a racial composition as follows: 72.0% White, 8.7% Native American, 7.4% African American, 1.7% Asian, and 10.2% of other races according to the 2000 census data. Three patients were from China, and the samples were provided by our collaborator. The peripheral blood samples were collected from patients and their parents. This study was approved by the ethical committee of the First Hospital of Jilin University and by the Institutional Review Board of the University of Oklahoma Health Sciences Center, respectively. Informed consent forms were signed by the patients or their guardians, in compliance with the Declaration of Helsinki.

Microarray Tests and Karyotype Analysis {#S2.SS2}
---------------------------------------

Genomic DNA was isolated from the peripheral blood samples using the Maxwell RSC Blood DNA kit (Promega) as per the manufacturer's instructions. Comparative genomic hybridization (CGH) assays were conducted with the SurePrint HD array (2 × 400 K V.1.0, Agilent Inc.), which was designed to detect CNVs across the whole genome. Of note is that the array contained 400 K oligonucleotides with a median probe spanning of ∼5.3 kb that represented the coding and the non-coding sequences in the human genome. The DNA samples from healthy individuals were used as controls for data analysis. We analyzed the CGH array data using the CytoGenomics software provided by Agilent.

Whole-genome single nucleotide polymorphism (SNP) array tests were executed by utilizing the Infinium CytoSNP-850K kit (v1.1 BeadChip, Illumina), following the manufacturer's guidelines. Specifically, the Illumina chip contained nearly 850,000 empirically selected SNPs spanning the whole genome. The average inter-probe distance was approximately 1.8 kb, and the overall effective resolution was around 18 kb. The processed chip was scanned on the NextSeq550 system (Illumina). The data were analyzed using the BlueFuse Multi v4.3 software (Illumina).

Cell preparation and karyotype analysis were performed as previously reported ([@B27]). For each patient, 20 metaphase cells were analyzed by G-banding.

Targeted Sequencing and Whole-Exome Sequencing {#S2.SS3}
----------------------------------------------

The customized panel for oral--facial--digital (OFD) syndrome included five genes: C2CD3, CPLANE1, DDX59, OFD1, and TCTN3. Baits for the OFD gene panel and whole-exome sequencing (WES), which targeted on comprehensive medical exomes, were purchased from Agilent. Both the targeted sequencing library and the WES library for patient 33 were constructed using the Agilent SureSelect clinical research exome kit, except that the hybrid captures were performed using different baits as described above. Sequencing was conducted on a NextSeq550 sequencer (Illumina) with 100 bp paired-end reads. The DNA sequence was aligned to the human reference genome (UCSC hg19). We built a sequence processing pipeline for analyzing both the targeted gene panel and the WES data by incorporating two commercial software, CLC biomedical genomic workbench from QIAGEN and AlamutBatch from Interactive Biosoftware. The evaluation and the classification of variants were performed following the American College of Medical Genetics (ACMG) recommendations ([@B35]).

Results {#S3}
=======

Molecular Characterizations of CNVs at 1q21.1 {#S3.SS1}
---------------------------------------------

We analyzed 5,200 microarray tests predominantly for pediatric patients with developmental delays, IDs, craniofacial abnormalities, congenital heart defects, and other abnormalities. Our investigation identified 38 individuals carrying either one copy of deletion or duplication at the 1q21.1 locus. Of note is that one patient had a 3.0-Mb deletion at 1q21.1 and an additional pathogenic deletion of ∼1.1 Mb at 17p13.2 (chr17:5,024,275--6,074,275). Another patient carried a proximal 1q21.1 duplication of ∼436 kb and an extra, likely pathogenic, deletion at 19p13.3 (chr19:259,395--1,045,363). After excluding those two cases, 36 individuals with either a deletion or a duplication at the 1q21.1 locus were subjected to further examinations. Notably, case 22 also carried one 1.1-Mb duplication at 13q21.33, and case 23 had a 409-kb deletion at 15q21.2. However, both the duplication at 13q21.33 and the deletion of 15q21.2 have not been reported as pathogenic in any patient with a disorder. In addition, the chromosomal analysis for 10 out of 36 cases all showed a normal karyotype. Our final subjects for systemic analyses included 31 probands with variable clinical manifestations and five individuals showing unnoticeable or very mild symptoms ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}).

Among those 36 cases, cases 1--18 each carried one deletion at 1q21.1, cases 19 and 20 had a 358-kb deletion at the proximal 1q21.1 region (TAR deletion), nine individuals (cases 21--29) bore a 1q21.1 duplication, and the remaining seven (cases 30--36) carried a proximal 1q21.1 duplication ([Figures 1A,B](#F1){ref-type="fig"}). The breakpoints among those cases varied dramatically, but all could be mapped to one of the segmental duplication blocks (BP1--BP4). Fourteen out of 18 deletions at 1q21.1 belonged to class I deletions, which occurred between BP3 and BP4 with a size range of 1.3--2.2 Mb, while the remaining four were categorized as class II deletions with larger sizes, ranging from 3.0 to 3.9 Mb and flanked by BP1/BP2 and BP4. Only two patients carried the typical TAR deletion of ∼350 kb ([Figure 1A](#F1){ref-type="fig"}) ([@B1]).

![Schematic representations of deletions **(A)** and duplications **(B)** at 1q21.1 (GRCh37/hg19, 144.0--149.5 Mb). Breakpoint regions (BP1--BP4) in dotted squares were delineated according to [@B34]. Class I, class II, and thrombocytopenia-absent radius (TAR) deletions (labeled as class I del, class II del, and TAR del) were drawn based on [@B9] with modification. In a similar way, class I, class II, and proximal 1q21.1 duplications were generated. We narrowed down the sizes of TAR deletions/proximal 1q21.1 duplications and class I deletions/duplications down to minimal sizes approximately 200 and 800 kb as being reported ([@B13]; [@B1]).](fgene-11-00577-g001){#F1}

Both class I and class II duplications at the 1q21.1 locus were likewise detected in our cohort. Specifically, we found class I duplications among eight individuals (cases 21--26 and cases 28 and 29) and a class II duplication in one patient (case 27) who carried the largest duplication of 4.9 Mb, flanked by BP1 and BP4 ([Figure 1B](#F1){ref-type="fig"}). Surprisingly, we identified seven individuals (cases 30--36) possessing proximal 1q21.1 duplications with a size range of 228 kb--1.1 Mb. Among them, cases 30 and 31, a mother and her daughter, carried the largest duplication of 1.1 Mb, spanning BP1 and BP3 ([Figure 1B](#F1){ref-type="fig"}).

Clinical Manifestations {#S3.SS2}
-----------------------

The phenotypes for individuals with 1q21.1 deletions are summarized in [Table 1](#T1){ref-type="table"}. Among 18 individuals who carried either a type I or a type II deletion, nine (50%) displayed growth delay with either height percentile, weight percentile, or both lower than 95% of the same age peers within the general population. Three of 18 (17%) had a significantly small head (2nd percentile head circumference), and no individual displayed macrocephaly. Mild to moderate dysmorphic facial features were recognized in 10 patients (56%). Cognitive and/or behavioral defects appeared as another relatively common phenotype, manifesting in 10 of 18 (56%) individuals. Other clinical features identified in at least two individuals included cardiac defects (five patients), constipation (five patients), failure to thrive (FTT; three patients), gastroesophageal reflux disease (three patients), ataxia (two patients), hypotonia (two patients), and uterus malformation (two female patients). Notably, three parents of four patients either presented with unrecognizable phenotypic features (case 5, mother of case 4) or only mild symptoms (case 7, father of cases 8 and 9; case 13, mother of case 14), even though they carried identical deletions as their children did. As shown in [Figure 2](#F2){ref-type="fig"}, the son and daughter displayed apparent dysmorphic facial anomalies and had profound IDs when compared to the father, suggesting incomplete penetrance and a variable expressivity of 1q21.1 deletion as reported by other groups ([@B9]; [@B34]; [@B46]; [@B11]). In general, no apparent distinct features were observed among the carriers of class I and class II deletions, which is consistent with previous reports ([@B9]; [@B34]).

###### 

Molecular characterization and phenotypical features for individuals with 1q21.1 deletions.

  Case   Age    Sex   Size     Growth features^a^   Head size (percentile) and facial features^b^                                                                    Cognitive and behavioral features                                Cardiac anomalies                            Additional clinical features                                                                                                                           Notes
  ------ ------ ----- -------- -------------------- ---------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- -------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ -------------
  1      3 Y    M     1.8 Mb   0%; 0%               Normal; normal                                                                                                   No                                                               No                                           FTT, delayed bone age (\<2 SD of the mean), constipation                                                                                               ∼
  2      3 Y    M     1.3 Mb   3%; 7%               Microcephaly (0%); dysmorphic facial features, possible Pierre Robin sequence                                    Speech and fine motor delays                                     No                                           Constipation, eczema                                                                                                                                   ∼
  3      5 Y    F     2.1 Mb   85%; 95%             Normal; esophoria                                                                                                Speech, motor skills and cognition delays, behavioral concerns   PFO, PDA                                     Gastroschisis, esophagus stenosis, proteinuria, constipation                                                                                           ∼
  4      10 M   M     3.0 Mb   74%; 64%             Normal; normal                                                                                                   No                                                               Systolic heart murmur                        Type-1 laryngeal cleft, ankyloglossia, GERD, dysphagia, tonsillar hypertrophy                                                                          ∼
  5      36 Y   F     3.0 Mb   N/A                  Normal; normal                                                                                                   No                                                               No                                           No                                                                                                                                                     MOC 4
  6      6 Y    M     1.2 Mb   2%; 16%              Normal; normal                                                                                                   Fine motor and mild gross motor delays                           Ascending aorta dilatation, bicuspid valve   Laryngotracheomalacia, GERD, connective tissue disorder, hydrocele, bilateral eustachian tube dysfunction                                              ∼
  7      36 Y   M     1.3 Mb   N/A                  Normal; prominent nasal bridge, mild micrognathia                                                                No                                                               No                                           No                                                                                                                                                     FOC 8 and 9
  8      12 Y   M     1.7 Mb   N/A                  Normal; strabismus, prominent nasal bridge, deformed ears                                                        ID                                                               No                                           Tapered fingers, ataxia, abnormal eye movement                                                                                                         ∼
  9      5 Y    F     1.7 Mb   15%; 1%              Normal; strabismus, deformed ears, hypertelorism, pointed chin                                                   ID                                                               No                                           Tapered fingers, ataxia, abnormal eye movement                                                                                                         ∼
  10     11 Y   F     1.3 Mb   1%; 1%               Normal; normal                                                                                                   ADHD, ID, disruptive behavior disorder, anxiety                  PDA                                          Congenital megaureter, dysfunction bladder, solitary kidney, short stature                                                                             ∼
  11     16 M   M     1.3 Mb   0%; 0%               Normal; dropped upper eyelids with bilateral colobomas                                                           No                                                               No                                           Hypotonia, dysphagia, laryngomalacia, glottic stenosis, FTT, inguinal hernia, GERD, phimosis                                                           ∼
  12     23 Y   F     1.3 Mb   N/A                  N/A                                                                                                              No                                                               No                                           Bicornuate uterus, two preterm deliveries with one fetal demise who also carries the deletion                                                          ∼
  13     23 Y   F     2.2 Mb   N/A                  Normal; high-arched eyebrows                                                                                     Bipolar                                                          No                                           No                                                                                                                                                     MOC 14
  14     3 Y    F     2.2 Mb   1%; 7%               Microcephaly (\<1%); high arched eyebrows, medial epicanthal folds, retrognathic jaw with protruding upper lip   Mild social and speech delays                                    No                                           Constipation, FTT                                                                                                                                      ∼
  15     21 M   F     1.8 Mb   27%; 74%             Normal; mild hypotelorism, large and cupped ears                                                                 ID, speech and motor delay                                       No                                           No                                                                                                                                                     ∼
  16     21 M   F     1.5 Mb   0%; 7%               Microcephaly (1%); normal                                                                                        Disruptive behavior, ID, speech delay                            PFO                                          Hypotonia, seizure, apnea, dysphagia, constipation, tongue-tie                                                                                         ∼
  17     16 Y   M     2.5 Mb   2%; 70%              Normal; normal                                                                                                   No                                                               No                                           Aplasia of uterus, forearm deformity with radial hypoplasia, underdeveloped hand; clinical features suggestive of Mayer-Rokitansky syndrome            ∼
  18     12 Y   M     3.9 Mb   76%; 54%             Normal; low posterior hairline, synophrys, mouth with high-arched palate, dental crowding, small chin            Learning difficulties, behavior disorders                        No                                           Long and webbing neck                                                                                                                                  ∼
  19     19 M   M     358 Kb   1%; 28%              Normal; normal                                                                                                   N/A                                                              PFO, small PDA                               Bilateral absent radii with shortened forearm, thrombocytopenia, TAR syndrome                                                                          ∼
  20     26 M   F     358 Kb   1%; 0%               Microcephaly (0.1%); nystagmus                                                                                   Speech delay                                                     No                                           Extreme prematurity (23 weeks), moderate hearing loss, adenoids hypertrophy, agenesis of the corpus callosum, hypotonia, spastic cerebral palsy, FTT   ∼

a

Growth features are illustrated by height percentile followed by weight percentile;

b

Head size is represented by head circumference percentile. ADHD, attention-deficit/hyperactivity disorder; FTT, failure to thrive; GERD, gastroesophageal reflux disease; ID, intellectual disabilities; PDA, patent ductus arteriosus; PFO, patent foramen ovale; MOC, mother of case; FOC, father of case; N/A, not available.

![Photos of one family with 1q21.1 deletions (cases 7--9). **(A)** The father with mild dysmorphic facial features and the son with intellectual disabilities, strabismus, deformed ears **(B)**, and tapered fingers **(C)**. **(D,E)** The daughter has intellectual disabilities. Like her elder brother, she also manifested with strabismus, pointed chin and deformed ears **(D)**, and tapered fingers **(E)**.](fgene-11-00577-g002){#F2}

Two patients who carried the TAR deletion displayed non-overlapping clinical features despite sharing an identical 358-kb deletion ([Table 1](#T1){ref-type="table"}). Patient 19 had the characteristic features of TAR syndrome---bilateral absent radii with shortened forearm and thrombocytopenia. This patient received a clinical diagnosis of TAR syndrome prior to receiving the result of the microarray test. Patient 20 was an extremely premature infant (born at 23 weeks) with agenesis of the corpus callosum, hypotonia, seizures, and mild hearing loss. It was not clear if this infant could be diagnosed with TAR syndrome because of the lack of typical clinical features. TAR syndrome was recently classified as an autosomal recessive disorder ([@B28]); however, the patient's DNA sample was not available to test if she carried another pathogenic variant in trans.

We also outlined in [Table 2](#T2){ref-type="table"} the clinical features of nine individuals with 1q21.1 duplications and seven with proximal 1q21.1 duplications. Contrastingly, the undergrowth phenotype found in patients with 1q21.1 deletions was mostly replaced by overgrowth in patients with 1q21.1 duplications: four out of nine patients exhibited overgrowth of either height, weight, or both in the top 2 percentile. Cognitive and behavioral issues were typical for patients with 1q21.1 duplications, identified in two-thirds of the patients (six out of nine). Autistic features were observed in 33% (three out of nine) of patients. Other common clinical phenotypes included macrocephaly/mild dysmorphic facial features (three patients) and cardiac anomalies (three patients). In addition, two male infants, one 14-month-old (case 23) and one 23-month-old (case 24), with 1q21.1 duplications exhibited hearing loss. It is worth mentioning that the patients' ages varied from 1 month to 14 years. Certain clinical features, for instance, psychiatric problems, might not be recognizable in infants. In those nine patients, only one (case 27) carried a class II duplication of 4.9 Mb, and the remaining eight patients had class I duplications with somewhat similar sizes at around 1.3 Mb. Phenotypically, class I and class II duplications were indistinguishable as illustrated in earlier reports ([@B9]; [@B34]; [@B36]).

###### 

Molecular characterization and phenotypical features for individuals with 1q21.1 duplications.

  Case   Age     Sex   Size     Growth features^a^   Head size (percentile) & facial features^b^                                    Cognitive and behavioral features                 Cardiac anomalies                                                                                  Additional clinical features                                                                                                                           Notes
  ------ ------- ----- -------- -------------------- ------------------------------------------------------------------------------ ------------------------------------------------- -------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ --------
  21     6 Y     F     1.3 Mb   99%; 100%            Macrocephaly (98%); up slanting palpebral fissures, helix folded ears          Speech delay                                      No                                                                                                 Port-Wine stain on neck, fifth finger brachydactyly, sandal gap feet                                                                                   
  22     1 M     F     1.3 Mb   11%; 38%             Normal; normal                                                                 N/A                                               PDA, ASD, tricuspid regurgitations, Epstein anomaly                                                Tachycardia                                                                                                                                            
  23     14 M    M     1.3 Mb   2%; 0%               Normal; normal                                                                 No                                                TOF with pulmonary atresia                                                                         Hearing loss, feeding difficulties                                                                                                                     
  24     23 M    M     1.3 Mb   24%; 92%             Normal; normal                                                                 Speech and gross motor delays                     PFO                                                                                                Hypotonia, bilateral metatarsus adductus, gait abnormalities, hearing loss, congenital anomaly of great vein, phimosis                                 
  25     14 Y    M     1.2 Mb   70%; 99%             Macrocephaly (99%); flat nasal bridge                                          Speech and fine motor delays                      No                                                                                                 Autism, Tourette syndrome, Sydenham chorea, hippocampal volume loss, hepatosplenomegaly, constipation, myopia, inguinal hernia, acanthosis nigricans   
  26     3 Y     M     1.3 Mb   98%; 87%             Normal; normal                                                                 No                                                No                                                                                                 Imperforate anus with perineal fistula                                                                                                                 
  27     13 Y    F     4.9 Mb   11%, 61%             Macrocephaly (98%); mildly overfolded ears                                     Speech disorder, behavioral problem, ADHD         No                                                                                                 Autism, anemia                                                                                                                                         
  28     8 Y     M     1.5 Mb   97%, 99%             Normal; normal                                                                 ID, speech and fine motor delays, ADHD            No                                                                                                 No                                                                                                                                                     
  29     5 Y     M     1.9 Mb   39%; 53%             Normal; normal                                                                 Behavior problem, speech and motor delays, ADHD   No                                                                                                 Autism                                                                                                                                                 
  30     25 Y    F     1.1 Mb   N/A                  Normal; normal                                                                 No                                                No                                                                                                 N/A                                                                                                                                                    MOC 31
  31     1.5 M   F     1.1 Mb   7%; \<3%             Microcephaly (0.1%); normal                                                    No                                                Balanced complete atrioventricular canal with aortic arch hypoplasia, ASD, enlarged right atrium   Leftward stomach                                                                                                                                       
  32     18 M    F     228 Kb   95%; 97%             Macrocephaly (100%); mild facial dysmorphism                                   Speech and motor skill delays                     No                                                                                                 Encephalomalacia, mild retinopathy, keratosis pilaris on thighs, mild hypotonia                                                                        
  33     24 Y    M     341 Kb   99%; 37%             Normal; brachycephalic, short forehead, triangular shaped face, micrognathia   Verbal apraxia, ID, anxiety.                      ASD                                                                                                Polydactyly, arachnoid cyst                                                                                                                            
  34     29 Y    F     359 Kb   N/A                  N/A                                                                            Bipolar, ID                                       No                                                                                                 Epilepsy, hypoglycemia                                                                                                                                 MOC 35
  35     18 M    F     359 Kb   6%; 86%              Normal; normal                                                                 No                                                No                                                                                                 Epilepsy, oropharyngeal dysphagia, vesicoureteral reflux, hydronephrosis, history of IUGR                                                              
  36     5 M     M     622 Kb   95%; \>97%           Normal; normal                                                                 No                                                PFO, ASD                                                                                           Congenital hydrocephalus, hydronephrosis, epilepsy, cortical blindness with retinal detachment, absent optic nerves                                    

a

Growth features are illustrated by height percentile followed by weight percentile;

b

Head size is represented by head circumference percentile. ASD, atrial septal defects; ADHD, attention-deficit/hyperactivity disorder; ID, intellectual disabilities; IUGR, intrauterine growth restriction; PDA, patent ductus arteriosus; PFO, patent foramen ovale; TOF, tetralogy of Fallot; MOC, mother of case; FOC, father of case; N/A, not available.

The seven individuals with proximal 1q21.1 duplications included the two mothers (cases 30 and 34) and their daughters (cases 31 and 35). Of those two mothers, case 30 was healthy, and case 34 exhibited mild symptoms comprising of bipolar, ID, and epilepsy. Overall, the patients in this group showed more diverse clinical features. For example, the 1.5-month-old infant manifested microcephaly (case 31), and the 18-month-old showed macrocephaly (case 32). However, typical phenotypes were indeed prominent, such as cardiac defects (three patients or 43%), epilepsy (three patients), cognitive and behavioral problems (three patients), and retina defects (two patients). Case 33 was unique, a 24-year-old male with syndactyly and polydactyly. The patient was born with six fingers on his left hand, seven fingers on his right hand, seven toes on his left foot, and six toes on his right foot. The extra digits were surgically removed ([Figure 3](#F3){ref-type="fig"}). This patient also displayed dysmorphic facial features including brachycephaly, short forehead, triangular-shaped face, micrognathia, submucosal cleft, similar to the phenotypes of OFD syndrome VI. However, both targeted sequencing of OFD syndrome-related genes (C2CD3, CPLANE1, DDX59, OFD1, and ICTN3) and whole-exome sequencing turned out to be negative ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}). In addition, this patient also demonstrated ASD and arachnoid cysts. He exhibited verbal apraxia, and his latest intelligence quotient score was 41, far below average.

![Deformed hands and feet for case 33 with a proximal 1q21.1 duplication. The patient was born with severe syndactyly and polydactyly, including six fingers on left hand **(A)**, seven fingers on right hand **(B)**, seven toes on left foot **(C)**, and six toes on right foot **(D)**. Extra fingers and toes were surgically removed. However, syndactyly is still visible on his right hand **(B)** and feet **(C,D)**.](fgene-11-00577-g003){#F3}

Discussion {#S4}
==========

Chromosomal microarray (CMA) technologies, including SNP array and CGH array, are powerful tools for the investigation of chromosomal abnormalities. The applications of CMA technologies have led to the discovery of pathogenicity in many patients with developmental delay ([@B40]), IDs ([@B16]; [@B37]), congenital heart defects ([@B12]), autism ([@B39]; [@B32]), and schizophrenia ([@B25]; [@B42]). The guidelines regarding how to implement those technologies and how to interpret the findings clinically have been published by the ACMG and other medical associations ([@B31]; [@B30]; [@B2]; [@B3]). As a CAP-certified clinical genetic laboratory, we have been utilizing CMA technologies in patients with developmental delays, IDs, and other anomalies since 2008, particularly focusing on children and, occasionally, their parents. A frequent observation of copy number changes at 1q21.1 in patients with diverse clinical manifestations triggered our investigation into the molecular characteristics of CNVs and the genotype--phenotype correlation.

In this study, we reported 36 cases with comprehensive, recurrent deletions and duplications at the 1q21.1 locus. To our knowledge, this is the first study that covers all four distinct types of copy number changes at this region in patients with variable symptoms. The sizes of deletions and the reciprocal duplications in the 1q21.1 region varied, ranging from 1.2 Mb (case 25) to 4.9 Mb (case 27). Nevertheless, each of those CNVs encompassed at least a minimal class I deletion/duplication of ∼800 kb and comprised seven genes ([@B7]) ([Figure 4](#F4){ref-type="fig"}). The breakpoints of deletions and duplications were mapped to the four breakpoint regions (BP1--BP4). Specifically, 22 out of 27 deletions/duplications at the 1q21.1 region occurred between BP3 and BP4; the remaining five took place in the middle of BP1/BP2 and BP4 ([Figures 1A,B](#F1){ref-type="fig"}). All nine proximal deletions/duplications likewise contained the minimal 200-kb segment in the proximal 1q21.1 region defined by [@B28]. Two patients carried the typical 1q21.1 proximal deletion of approximately 350 kb (cases 19 and 20). In contrast, the remaining seven individuals had diverse duplications in the proximal 1q21.1 region with a size range of 228 kb--1.1 Mb. The causation of the diverse deletions and duplications in the region has been proposed by [@B34]. As shown in [Figure 4](#F4){ref-type="fig"}, hundreds of fragments with sizes of 10--300 kb and sequence similarities varying from 95 to 99.9% cluster in four segmental duplication regions. Low copy repeats make this region vulnerable for NAHR during meiosis and mitosis, and this could contribute to the creation of deletions or duplications in daughter cells ([@B33]).

![Segmental duplications and Online Mendelian Inheritance in Man (OMIM) documented genes at the 1q21.1 region. Breakpoint regions (BP1--BP4) in dotted squares were delineated according to [@B34]. Highlighted in light blue was the minimal thrombocytopenia-absent radius deletion/proximal 1q21.1 duplication region; the blue-colored band represented the core region of class I deletions/duplications. Low copy repeats with varied sequence similarity were highlighted with different colors. Light to dark gray: 90--98%, light to dark yellow: 98--99%, and light to dark orange: \>99%. The figure was generated using the University of California, Santa Cruz Genome Browser ([@B6], [@B5]). Green color genes: the molecular mechanism for the gene-associated disorders has been demonstrated. Gray color genes: the gene-related OMIM phenotype was not available.](fgene-11-00577-g004){#F4}

Hundreds of copy number changes at 1q21.1 have been reported in several large cohort studies targeted for developmental delays, IDs, congenital anomalies, autism, and schizophrenia ([@B9]; [@B34]; [@B42]; [@B26]; [@B13]; [@B38]). Consequently, those studies and others have led to two newly accepted autosomal dominant syndromes: chromosome 1q21.1 deletion syndrome and chromosome 1q21.1 duplication syndrome ([@B17]). Case studies and small-scale investigations focusing on the syndromes have been occasionally published in recent years ([@B24]; [@B44]; [@B45]; [@B7]; [@B46]; [@B11]). Detailed information regarding deletions and duplications at the 1q21.1 locus are summarized in [Supplementary Table S2](#TS2){ref-type="supplementary-material"}. Nevertheless, both the 1q21.1 deletion syndrome and the 1q21.1 duplication syndrome are rare disorders, and additional phenotypic features are necessary to precisely define the disorders further. Particularly, there are only a few reports in connection with proximal 1q21.1 duplications ([Supplementary Table S2](#TS2){ref-type="supplementary-material"}). The molecular characterization and the clinical consequence of proximal 1q21.1 duplications remain largely unknown.

Our study adds 27 new cases and offers new insights to 1q21.1 deletion and duplication syndromes. First, common features appeared in patients with 1q21.1 deletions, such as microcephaly, undergrowth, mild to moderate dysmorphic facial features, ID, psychiatric disorders, short stature, and cardiac anomalies despite the absence of one clinical feature common among all or the majority of patients ([Table 1](#T1){ref-type="table"}). The observations are consistent with two seminal studies by [@B34] and [@B9], respectively. Moreover, typical clinical characters were recognized in patients carrying 1q21.1 duplications as well. For example, speech delay was found in two out of three patients; macrocephaly and autistic features were identified in one out of three probands. We also observed diverse clinical manifestations---three patients' weight percentiles were 99th percentile or above, while one 14-month male had a low weight percentile close to 0% (case 23). Other less common features in patients with 1q21.1 duplications included hand/foot dysmorphism, hearing loss, hypotonia, and hepatosplenomegaly ([Table 2](#T2){ref-type="table"}). Second, microcephaly and macrocephaly were associated with 1q21.1 deletions and reciprocal 1q21.1 duplications, respectively, consistent with previous reports ([@B9]; [@B34]; [@B36]). It has been proposed that the HYDIN2 gene, which is a paralog of the HYDIN gene at 16q22.2 and resides at the BP3 region, is dosage-sensitive and responsible for the head sizes in patients ([@B9]). However, this gene and its role in human diseases have not been curated in OMIM. DUF1220 sequences predominantly exist in neuroblastoma breakpoint family (*NBPF*) genes ([@B4]). By applying specialized bioinformatics tools for analyzing the CNVs of DUF1220 from 42 patients with either the 1q21.1 deletion or the reciprocal duplications, [@B19] proposed that the DUF1220 sequences in the NBPF genes were associated with brain size anomalies ([Figure 4](#F4){ref-type="fig"}). Lastly, autism seems common in patients with 1q21.1 duplications in this study, consistent with other reports ([@B39]; [@B9]; [@B32]). It has been proposed that DUF1220 dosage contributes to the disease severity of autism patients ([@B15]), yet the direct linkage from the DUF1220 copy numbers to the brain sizes and the severe autistic features of patients still need to be investigated extensively in the future. Of note is that no patient carrying 1q21.1 deletions displayed symptoms related to schizophrenia as being depicted earlier ([@B25]; [@B42]), and this is probably due to the fact that most of our patients were too young (\<11 years).

Thrombocytopenia-absent radius syndrome was recognized in the 1950s ([@B22]; [@B41]), yet the genetic etiology was not fully understood until recently ([@B28]; [@B1]). [@B28] investigated 30 unrelated patients diagnosed with TAR syndrome and found that all patients carried one common deletion at the proximal 1q21.1 region with a size range of 200--500 kb. It is now believed that TAR syndrome is an autosomal recessive disease caused by mutations in the RBM8A gene, typically including a null allele and a non-coding SNP in the 5-terminal for the other allele ([@B1]). Two patients in this study carried a proximal 1q21.1 deletion. One patient (case 19) needed frequent platelet transfusions and was diagnosed as TAR syndrome before our test, while the other patient (case 20) did not display the characteristic features of TAR syndrome. It was not clear if the patient carried an additional mutation on the other allele or whether the symptoms were directly associated with the proximal 1q21.1 deletion. Alternatively, patient 20 was a carrier of a proximal 1q21.1 deletion, and the clinical features were partially or solely related to the premature delivery. It is worth noting that there are fewer patients with proximal 1q21.1 deletion in this study because TAR syndrome can be diagnosed without genetic testing ([@B23]).

Unlike proximal 1q21.1 deletions which have been associated with TAR syndrome, there are still lots of unknowns for proximal 1q21.1 duplications. By studying a large cohort of 15,767 children with ID and other congenital abnormalities as well as 8,329 health controls, [@B13] reported that 26 patients in the disease cohort and only one individual in the control group carried a proximal 1q21.1 duplication, a significant enrichment with an odds ratio of 13.71 (*p* = 0.0002). Another study was jointly performed by multiple institutions in the United States which identified 20 probands with proximal 1q21.1 duplications; the clinical features identified in four or more patients included facial anomalies, FTT/feeding problems, ID/developmental disabilities, clinodactyly, skeletal limb defects, and autistic features ([@B36]). Our study incorporates seven more cases with proximal 1q21 duplications into the pool of this rare disorder. Of note is that case 30 had no recognizable clinical phenotypes, but her newborn daughter (case 31) had a head circumference below 99.9% of her same-age peers, cardiac defects, and leftward stomach, suggesting incomplete penetrance of the proximal 1q21.1 duplication. Case 33, a 24-year-old male, exhibited severe dysmorphic facial characters, polydactyly, language delay, ID, and ASD. Those characteristics resemble the phenotype of one early reported case ([@B8]). The findings suggest that proximal 1q21.1 duplications highly likely contributed to the clinical phenotypes in patients. However, whether other genetic or environmental factors are also involved requires further explorations, especially considering that compound heterozygous mutations, including a proximal 1q21.1 deletion, are essential for TAR syndrome.

Segmental duplications at the 1q21.1 locus promote unequal crossing over and compromise the genomic stability in this region ([@B34]; [@B33]). Because of the broad applications of CMA technologies in clinical diagnoses, more and more patients with CNVs in this region have been recognized. Apart from TAR syndrome which can be recognized easily based on the typical clinical feature and dramatically reduced blood platelet counts, the other three disorders, including proximal 1q21.1 duplication and chromosome 1q21.1 deletion/duplication syndromes, are difficult to be recognized clinically owing to variable expressivity and incomplete penetrance. Consequently, diagnoses should be more or less dependent on genetic testing, such as CMA technologies or next-generation sequencing-based assays. The characterization of each disorder also poses significant challenges for genetic counseling that requires both careful clinical evaluation and accurate genetic testing.

Conclusion {#S5}
==========

Our large cohort study in patients with developmental delays, head and facial abnormalities, cardiac defects, psychiatric issues, and other anomalies reinforced that the subchromosomal region 1q21.1 (GRCh37/hg19, chr1:144.0--149.5 Mb) was a hotspot for deletions and duplications due to the presence of hundreds of low copy repeats. In this study, we identified diverse copy number changes at the 1q21.1 locus, including class I/II deletions, class I/II duplications, proximal 1q21.1 deletions, and reciprocal 1q21.1 duplications. Deletions and duplications in the 1q21.1 region have been associated with three syndromes, including chromosome 1q21.1 deletion syndrome, chromosome 1q21.1 duplication syndrome, and TAR syndrome. Our findings provided valuable information for those rare syndromes, both on the molecular characteristics of deletions/duplication and on the phenotypic diversity. Most importantly, our study identified seven cases with recurrent duplications in the proximal 1q21.1 region, indicating that the variants highly likely contribute the clinical manifestations in patients.

We also observed incomplete penetrance and variable expressivity to be related to copy number changes at the 1q21.1 locus. The findings suggest that the diagnoses of disorders associated with CNVs at 1q21.1 require not only careful clinical evaluation but also accurate genetic tests.

Data Availability Statement {#S6}
===========================

The datasets for this article are not publicly available due to concerns regarding participant/patient anonymity. Requests to access the datasets should be directed to the corresponding author.

Ethics Statement {#S7}
================

The studies involving human participants were reviewed and approved by the Institutional Review Board (IRB) of the University of Oklahoma Health Sciences Center, the ethical committee of the First Hospital of Jilin University. Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin. Written informed consent was obtained from the individual(s), and minor(s)' legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.

Author Contributions {#S8}
====================

HG and SL designed the study, analyzed the data, and drafted the manuscript. HP and XY participated in collecting the patients' information and in data analysis and wrote the manuscript. YK, XW, JJ, and JY conducted the tests and performed the result interpretation. All authors contributed to the article and approved the submitted version.

Conflict of Interest {#conf1}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

We thank all members and alumni of the Genetics Laboratory at the University of Oklahoma Health Science Center (OUHSC) who have contributed to this study directly or indirectly. We also thank the physicians in the Children's Hospital of OUHSC who provided detailed clinical information for the patients reported here. Without the agreement and participation of our patients and their guardians, this study could not have been done properly. Two figures ([Figures 1](#F1){ref-type="fig"}, [4](#F4){ref-type="fig"}) were generated utilizing the University of California, Santa Cruz Genome Browser.

Supplementary Material {#S10}
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fgene.2020.00577/full#supplementary-material>

###### 

Click here for additional data file.

###### 

Click here for additional data file.

[^1]: Edited by: Lawrence Todd Reiter, The University of Tennessee Health Science Center (UTHSC), United States

[^2]: Reviewed by: Thomas Liehr, Friedrich Schiller University Jena, Germany; Joseph Glessner, Children's Hospital of Philadelphia, United States

[^3]: ^†^These authors have contributed equally to this work

[^4]: This article was submitted to Genetic Disorders, a section of the journal Frontiers in Genetics
